Hefei Cosource Pharmaceutical

Hefei Cosource Pharmaceutical is a private Chinese pharmaceutical company focused on the research, development, and production of innovative drugs—primarily small molecules—for oncology, cardiovascular, hematological, and nervous system diseases. Its lead asset is HYML‑122 for FLT3-positive acute myeloid leukemia in Phase 2 trials. Other assets include sabarubicin hydrochloride for refractory small cell lung cancer and HYC‑11395 for thrombosis in early clinical stages. The company also provides integrated R&D services including synthesis techniques, safety assessment, pharmacokinetics studies, and clinical trial support.